Arvinas (NASDAQ:ARVN - Get Free Report)'s stock had its "market perform" rating restated by equities research analysts at Leerink Partners in a report issued on Monday, MarketBeat.com reports. They currently have a $9.00 price target on the stock, down from their previous price target of $10.00. Leerink Partners' price objective would suggest a potential upside of 32.74% from the company's current price.
Several other analysts also recently weighed in on the stock. Jefferies Financial Group restated a "hold" rating and set a $10.00 price objective (down previously from $52.00) on shares of Arvinas in a research report on Friday, May 2nd. UBS Group reduced their price objective on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. BMO Capital Markets reduced their price objective on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research report on Monday, May 5th. Piper Sandler restated an "overweight" rating and set a $14.00 price objective (down previously from $24.00) on shares of Arvinas in a research report on Friday, May 2nd. Finally, HC Wainwright reduced their price objective on shares of Arvinas from $81.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, Arvinas currently has an average rating of "Moderate Buy" and a consensus price target of $20.29.
Check Out Our Latest Report on ARVN
Arvinas Price Performance
Shares of ARVN stock traded down $0.17 during trading on Monday, reaching $6.78. The company's stock had a trading volume of 1,129,451 shares, compared to its average volume of 1,383,517. The company has a market capitalization of $494.88 million, a price-to-earnings ratio of -2.45 and a beta of 2.21. The stock's 50-day moving average price is $7.27 and its 200 day moving average price is $14.35. Arvinas has a 1-year low of $5.90 and a 1-year high of $34.11.
Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the company earned ($0.97) earnings per share. The firm's revenue was up 646.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.
Insider Transactions at Arvinas
In related news, insider Noah Berkowitz sold 8,658 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. This trade represents a 7.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.73% of the company's stock.
Institutional Investors Weigh In On Arvinas
A number of large investors have recently added to or reduced their stakes in ARVN. T. Rowe Price Investment Management Inc. acquired a new stake in Arvinas in the 4th quarter valued at about $42,332,000. Alyeska Investment Group L.P. acquired a new stake in Arvinas in the 1st quarter valued at about $12,636,000. Vanguard Group Inc. grew its stake in Arvinas by 18.4% in the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock valued at $58,703,000 after acquiring an additional 1,299,639 shares during the last quarter. Norges Bank acquired a new stake in Arvinas in the 4th quarter valued at about $23,845,000. Finally, Boxer Capital Management LLC acquired a new stake in Arvinas in the 4th quarter valued at about $20,294,000. 95.19% of the stock is owned by institutional investors and hedge funds.
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Further Reading
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
